No Data
No Data
Why Structure Therapeutics Stock Was Stumbling This Week
SA Asks: What's the Most Attractive Weight-loss Stock Right Now?
Metsera Sees Stock Rally 54% Following $275M IPO
Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences
Piper Sandler Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $93
Structure Therapeutics, Inc. Sponsored ADR (GPCR) Gets a Buy From Piper Sandler
Unlock the Full List